The action of somatostatin analogues, such as octreotide or lanreotide, which inhibit gastrin secretion and consequent enterochromaffin cell proliferation, provides a mechanism to block the hyperplasia and dysplasia that eventually leads to neoplasia, and could thus prevent the appearance of GC-1. The gene discussed is GAST; the disease is neoplasm.